A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)

NCT03844074 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

61

Enrollment

INDUSTRY

Sponsor class

Conditions

Age-related Macular Degeneration
Neovascular Age-related Macular Degeneration
Wet Macular Degeneration

Interventions

BIOLOGICAL: bevacizumab
BIOLOGICAL: ranibizumab

Sponsor

Outlook Therapeutics, Inc.